Navigation Links
Protein Sciences Announces Termination of Deal to Sell to Emergent BioSolutions
Date:7/29/2008

nnounced that it reached an important milestone related to FluBlok when it successfully produced the vaccine necessary to combat each of the three strains that will make up the influenza vaccine for the 2008-2009 flu season.

PSC also announced that it submitted a proposal for federal funding for a contract to develop recombinant seasonal and pandemic influenza vaccines from the Department of Health and Human Services (BARDA). Negotiations over the contract have been ongoing and a decision may be reached by BARDA within the next few weeks. PSC has requested funding for, among other things, additional clinical trials to support pediatric and pandemic formulations of FluBlok; purchase of equipment for large scale manufacturing; and process and manufacturing facility validation as specified in the Request for Proposal issued by BARDA in 2007. If the contract is awarded, PSC expects that the work and funding will be spread over a five-year period.

About PSC. PSC is a privately held biotechnology company that uses proprietary recombinant DNA technology to manufacture human and animal vaccines, therapeutics and diagnostics. Our lead product is a human seasonal flu vaccine -- FluBlok(R). Our underlying technology is a viable alternative production platform to the egg-based production methods that currently dominate vaccine production and our 2007 revenues were in excess of $6,000,000, primarily from our GeneXpress and research antigen business.


'/>"/>
SOURCE Protein Sciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
2. China-Biotics, Inc. Launches Shining Probiotics Protein Powder
3. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
4. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
7. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
8. STALLERGENES and Protein eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Decision Biomarkers Launches System for Faster, Easier Quantification of Protein Biomarkers
11. Immune system protein starves staph bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... optimized Erk inhibitor molecule for development, thus achieving ... new class of potential cancer therapies. ... for therapeutic intervention in cancer. Recently approved compounds ... B-Raf and Mek inhibitors. Erk inhibitors may be ...
(Date:7/29/2015)... ... July 29, 2015 , ... Available in ... Express Contouring Bi-Gel, a nighttime-specific product that targets fat cells for extreme contouring ... able to enter fat cells, inhibiting the formation of new fat. Upon waking ...
(Date:7/29/2015)... ... 29, 2015 , ... Asymmetrex, LLC founder and ... the full range of capabilities of its unique cache of technologies for identifying, ... day-to-day renewal and repair of normal tissues and organs. This property makes them ...
(Date:7/28/2015)... ... July 29, 2015 , ... Strong Animals™ announced today that research conducted ... and presented at the ADSA-ASAS Joint Annual Meeting held July 12-16 in Orlando, FL ... and increased milk fat content. Also, feed containing Stay Strong™ for Dairy Cows took ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4Strong Animals™ Announces South Dakota State University Research Demonstrates Stay Strong™ for Dairy Cows Improves Performance and Feed Stability 2
... WEST LAFAYETTE, Ind. - Researchers have developed a ... "biosensors," a tool that could help industry perfect ... to environmental monitoring. , The experimental devices represent ... capture and detect specific "target molecules," which will ...
... the Board ... Neill Named President, ISELIN, N.J., Jan. 3 Pharmos Corporation,(Nasdaq: ... effective immediately., Board Changes, Robert F. Johnston has been elected ... and Mony Ben Dor have retired from,the Board., The Pharmos Board ...
... Jan. 3 Danaher Corporation (NYSE:,DHR) announced that ... will be presenting at the J.P. Morgan Healthcare ... 11:00 a.m. EST. The audio will be,simultaneously webcast ... on http://www.danaher.com for one week., ...
Cached Biology Technology:Model is first to compare performance of 'biosensors' 2Model is first to compare performance of 'biosensors' 3Pharmos Corporation Announces Board and Management Changes 2Pharmos Corporation Announces Board and Management Changes 3
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. ... of human interface solutions, today announced a ... first fully hardware encapsulated fingerprint sensor and ... technology is literally off the grid, isolating ... matching within the fingerprint sensor to provide ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... fact that they eat a lot and often may ... majority of fungal pathogens, according to research from Albert Einstein College ... the Journal of Infectious Diseases , showed that the elevated ... C in people is too high for the vast majority ...
... 15, 2009 / b3c newswire / - KINAXO ... that they will enter into collaboration. KINAXO will ... identification of novel biomarkers in a clinical trial ... allows annotation and quantification of regulated phosphorylation sites. ...
... Testicular cancer survivors can face an increased risk ... the highly effective treatment they receive, according to a ... Researchers from the Norwegian Radium Hospital at ... problems faced by survivors are higher than generally thought, ...
Cached Biology News:Do 3 meals a day keep fungi away? 2KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 2KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 3KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 4Treatment not testicular cancer poses greatest risk to survivors' long-term health 2Treatment not testicular cancer poses greatest risk to survivors' long-term health 3
... DASGIP Overhead Drive for individual and parallel ... flexible agitation of DASGIP vessels, featuring range ... ,Up to 16 overhead drives can ... Cultivation Systems fedbatch-pro® and cellferm-pro® for microbiology ...
... Whatever your Ion Chromatography requirements, IonQuest ... The newly developed conductivity detector has ... drift . In addition to the ... used with other detectors, such as electrochemical, ...
This pump accomodates StemSep ; pump feed columns of the following sizes : 0.3in., 0.5in., 0.6in., and 1.0in.....
...
Biology Products: